Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2025-04-08
DOI
https://doi.org/10.1186/s12885-025-14063-6
Citations
6
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
9.11
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical

Emanuela Dell’Aquila, Lorenzo Antonuzzo, Stefano Tamberi, Daniele Spada et al.
6 citations
BMC Cancer
Gastric Cancer Management and Outcomes
9.11
article

Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical

Emanuela Dell’Aquila, Lorenzo Antonuzzo, Stefano Tamberi, Daniele Spada, Alessandra Raimondi, Emiliano Tamburini, Andrea Spallanzani, Antonia Strippoli, Francesca Bergamo, Alberto Puccini, Lorenzo Fornaro, Federica Palermo, Federica Morano, Katia Bencardino, Salvatore Corallo, Vincenzo Nasca, Luisa Foltran, Samantha Di Donato, Filippo Pietrantonio, Chiara Alessandra Cella, Antonio Avallone, Oronzo Brunetti
article en
6 citations

Abstract

No abstract available for this paper.
BMC CancerVol. 25(1)
University of Modena and Reggio Emilia (IT), Humanitas University (IT), University of Pavia (IT), Cardinal Health (Australia) (AU), Agostino Gemelli University Polyclinic (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Istituto Oncologico Veneto (IT), Azienda Ospedaliero-Universitaria Careggi (IT), National Cancer Institute (UA), Centro di Riferimento Oncologico (IT), Istituto Tumori Bari (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Policlinico San Matteo Fondazione (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Ospedale di Prato Santo Stefano (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), IRCCS Humanitas Research Hospital (IT), Azienda Ospedaliera Universitaria Pisana (IT), Istituti Ospitalieri di Cremona (IT), Instituto Nazionale Tumori Regina Elena (IT), Azienda Socio Sanitaria Territoriale di Cremona, University of Florence (IT), European Institute of Oncology (IT)
Good health and well-being
Openalex Percentile: Top 2%
Gastric Cancer Management and Outcomes
9.11
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.